Firefly Health vs Eli Lilly

Side-by-side comparison of AI visibility scores, market position, and capabilities

Eli Lilly leads in AI visibility (81 vs 34)
Firefly Health logo

Firefly Health

EmergingHealthTech

Virtual Primary Care

Firefly Health operates a virtual-first primary care practice with dedicated care teams, offering comprehensive primary care, mental health, and chronic disease management through a mobile app.

AI VisibilityBeta
Overall Score
D34
Category Rank
#580 of 596
AI Consensus
77%
Trend
stable
Per Platform
ChatGPT
29
Perplexity
38
Gemini
36

About

Firefly Health delivers virtual-first primary care through a model built around dedicated care teams — a physician, health coach, and care coordinator assigned to each patient — rather than the on-demand provider matching used by most telehealth platforms. Patients access their care team through the Firefly app for video visits, messaging, lab result review, specialist referrals, and care plan management, with the team maintaining longitudinal knowledge of their health history and goals.

Full profile
Eli Lilly logo

Eli Lilly

LeaderHealthcare

General

Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.

AI VisibilityBeta
Overall Score
A81
Category Rank
#17 of 596
AI Consensus
71%
Trend
stable
Per Platform
ChatGPT
80
Perplexity
75
Gemini
77

About

Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.

Full profile

AI Visibility Head-to-Head

34
Overall Score
81
#580
Category Rank
#17
77
AI Consensus
71
stable
Trend
stable
29
ChatGPT
80
38
Perplexity
75
36
Gemini
77
31
Claude
86
31
Grok
85

Key Details

Category
Virtual Primary Care
General
Tier
Emerging
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Firefly Health
Virtual Primary Care

Integrations

Eli Lilly is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.